Amneal Pharmaceuticals vs Caris Life Sciences
Amneal Pharmaceuticals (AMRX), health care, and Caris Life Sciences (CAI), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Amneal Pharmaceuticals is worth $7.4B on the stock market and Caris Life Sciences $5.7B: Amneal Pharmaceuticals is valued at 29% more. Amneal Pharmaceuticals trades at 52.8 times earnings and Caris Life Sciences at 12.0; operating margins in their latest fiscal years were 13.1% and 5.56%. Over the past year Amneal Pharmaceuticals's share price has moved +83.5% and Caris Life Sciences's -11.6%.
Key facts
- Amneal Pharmaceuticals market value
- $7.4B
- Caris Life Sciences market value
- $5.7B
- Amneal Pharmaceuticals P/E
- 52.8
- Caris Life Sciences P/E
- 12.0
- Amneal Pharmaceuticals revenue
- $3BFY to 2025-12-31
- Caris Life Sciences revenue
- $812MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Amneal Pharmaceuticals | Caris Life Sciences |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $7.4Bhigher | $5.7Blower |
| Revenue | $3Bhigher | $812Mlower |
| Earnings | $72.1Mhigher | -$68.1Mlower |
| Employees | 8,700higher | 1,846lower |
| Total assets | $3.7Bhigher | $1.1Blower |
| Valuation | ||
| P/E | 52.8higher | 12.0lower |
| P/S | 2.4lower | 7.0higher |
| P/B | 13.8higher | 8.9lower |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | 13.1%higher | 5.56%lower |
| Balance sheet | ||
| Net assets | -$70.8Mlower | $577.3Mhigher |
| Total liabilities | $3.7Bhigher | $548.4Mlower |
| Total debt | $2.6Bhigher | $379Mlower |
| Cash on hand | $282Mlower | $796.3Mhigher |
| Price change | ||
| Today | -0.52%higher | -5.05%lower |
| 1 year | +83.5%higher | -11.6%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Amneal Pharmaceuticals only (0)
None of the tracked investors.
Caris Life Sciences only (2)
Percentages are each holding's share of that investor's reported portfolio. · Who owns CAI
More on Amneal Pharmaceuticals
Further comparisons
Amneal Pharmaceuticals against its closest peers
Caris Life Sciences against its closest peers
Learn
Questions and answers
Which is bigger, Amneal Pharmaceuticals or Caris Life Sciences?
By market value, Amneal Pharmaceuticals is the larger: $7.4B against $5.7B for Caris Life Sciences. By revenue in its latest fiscal year, Amneal Pharmaceuticals is the larger: $3B against $812M for Caris Life Sciences.
Which has the higher P/E ratio?
Amneal Pharmaceuticals: 52.8, against 12.0 for Caris Life Sciences. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Amneal Pharmaceuticals: 13.1%, against 5.56% for Caris Life Sciences. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
Amneal Pharmaceuticals: $2.6B, against $379M for Caris Life Sciences. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Amneal Pharmaceuticals and Caris Life Sciences?
None of the tracked superinvestors holds both in their latest 13F filing. 0 hold Amneal Pharmaceuticals and 2 hold Caris Life Sciences.
Cite this page
Funkfolio, “Amneal Pharmaceuticals vs Caris Life Sciences”, data as of 18 November 2026. https://funkfolio.com/compare/amrx-vs-cai
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.